The first gene therapy drug will be on the market

Source: qinyi 2014-12-12 in 2014, the development of gene drugs is springing up, sprouting one after another, and many gratifying results have been achieved Glybera, a gene therapy drug jointly developed by Dutch biotechnology company and Casey Pharmaceutical Group in 2014, will be listed in Germany for the treatment of genetic diseases due to lipoprotein esterase deficiency, which is also the first gene therapy drug to be listed With the development of gene technology and other high and new technologies, gene medicine will lead the future pharmaceutical industry Gene drugs or lead to the future subversion of the first gene therapy drugs will be on the market Gene drugs are used to treat gene abnormal diseases by introducing the expression of target genes into the body cells Compared with traditional drugs, gene drugs are used to treat diseases at the gene level They gradually show an irreplaceable role in the treatment of many chronic diseases, such as cancer, cardiovascular disease and so on All functions of human beings will be controlled by genes If we can make a breakthrough in the research of gene drugs, many problems of human diseases will be solved In recent years, more and more pharmaceutical companies at home and abroad have set foot in gene drugs, and invested a lot of money to develop new gene drugs to fight against various diseases In 2014, the development of gene drugs has mushroomed, sprouted one after another, and achieved many gratifying results The world's gene drug market is promising The first gene therapy drug will be listed in the world Today, Japan and the United States are the two countries with the largest investment in gene drug research The investment in genetic engineering drug research in the United States and Japan is up to billions of dollars every year Now, interferon, human erythropoietin, hepatitis B vaccine, tissue plasminogen activator, human insulin, human growth hormone, human granulocyte colony stimulating factor, human megaphagocyte colony stimulating factor and many other products have been successfully developed According to preliminary statistics, at present, there are as many as 100 kinds of genetic engineering drugs on the market in Europe and America, and nearly 300 genetic engineering drugs have entered clinical trials, and thousands of other varieties are still under research and development It is also reported that glybera, a gene therapy drug jointly developed by Dutch biotechnology company and Casey Pharmaceutical Group in 2014, will be listed in Germany for the treatment of genetic diseases due to lipoprotein esterase deficiency, which is also the first gene therapy drug to be listed This kind of gene medicine can make patients get the chance of rebirth by transferring the correction gene to the defective cell Compared with foreign countries, China's gene drug market has a late start and lacks the support of some high-tech R & D technology But in recent years, China has gradually attracted attention to this, and many pharmaceutical companies and R & D teams are increasingly interested in gene drugs With the support of various policies, Chinese pharmaceutical companies are also catching up in the research of gene drugs The market share of gene drugs such as domestic interferon α has even exceeded that of imported products Some industry insiders predict that China's gene and biological pharmaceutical industry will maintain a higher than the global average growth rate in the next few years and enter a rapid development track The development of scientific drug delivery system is the guarantee of gene drug efficacy, but it is worth mentioning that gene drug is easily degraded by ribozyme in the process of transportation in vivo, so as to weaken or eliminate the therapeutic effect of gene drug Therefore, a scientific and reasonable gene drug delivery system is needed to overcome the obstacles in the process of gene drug delivery and efficiently transport gene drugs to target cells for expression So, 2014 In, many research teams at home and abroad, including the Institute of process engineering of Chinese Academy of Sciences, carried out relevant research on gene drug delivery vehicles Starting from the relationship between the components, structure and function of carrier materials, researchers focused on the research and development of non viral delivery vehicles for gene drugs, aiming to develop some safe and efficient non viral gene transportation Carrier Although these projects have not yet been successful, they have gradually developed I believe they will make breakthroughs in the near future Conclusion: the market competition of gene drugs in 2014 is very fierce At present, gene drugs have the characteristics of high income, high risk, high investment and long cycle The huge R & D funds not only make it difficult for many pharmaceutical companies to support, but also make the high drug price difficult for ordinary patients to accept But one thing is for sure, once the large-scale preparation technology of gene drugs is broken through, the manufacturers can reduce the corresponding investment cost, thereby reducing the drug price of gene drugs, so that more patients benefit With the development of gene technology and other high and new technologies, gene medicine will lead the future pharmaceutical industry.